Sangamo is pioneering the future of genomic medicine
Sangamo Therapeutics is a genomic medicine company dedicated to translating groundbreaking science into medicines that transform the lives of patients and families afflicted with serious neurological disease. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from diseases for which today’s medicine can only offer symptom management at best.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
-
May 2, 2024
RICHMOND, Calif. --(BUSINESS WIRE)--May 2, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024 .
-
April 22, 2024
RICHMOND, Calif. --(BUSINESS WIRE)--Apr. 22, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27 th ASGCT Annual Meeting being held May
-
March 22, 2024
RICHMOND, Calif. --(BUSINESS WIRE)--Mar. 22, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an aggregate of 24,761,905 shares
-
March 13, 2024
Data from novel proprietary neurotropic adeno-associated virus (AAV) delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier (BBB) penetration in non-human primates (NHPs) following intravenous administration, with capsid-enabled delivery of zinc finger payloads targeting prion
Filing date | Form | Description | Filing Group | View |
---|---|---|---|---|
10-K | Annual report which provides a comprehensive overview of the company for the past year |
Annual Filings
|
View HTML | |
10-K | Annual report which provides a comprehensive overview of the company for the past year |
Annual Filings
|
View HTML | |
10-K | Annual report which provides a comprehensive overview of the company for the past year |
Annual Filings
|
View HTML |
-
May 9, 2024 at 4:30 PM EDT
-
May 14, 2024 from 8:30 AM to 8:55 AM EDT
-
Jun 6, 2024
-
Mar 13, 2024 at 4:30 PM EDT
-
Feb 7, 2024 at 8:00 AM PST